Don't Buy Neovasc Before Checking Its Margins!

Shares of Small-cap Medical Devices company Neovasc were up 30.3% during today's morning session, as the S&P 500 posted a -0.0% change. Today's upwards movement shows that investor interest in NVCN stock is strong — but how closely have they studied the company's margins?

While Neovasc's gross margins for the last year are positive, we are concerned that the company's operating margins are in the red. Gross margins take into account only the cost of revenue, or variable costs — meaning the cost directly associated with producing the products or providing the service offered by the company.

Operating margins, on the other hand, take into account the company's overhead as well. Overhead, also called fixed costs, includes the company's rent, salaries for personnel not included in cost of revenue, equipment and supplies, amortization, and depreciation. Operating margins tell you about how efficiently Neovasc is run, and gross margins tell you how profitable its product line is.

Date Reported Revenue ($ MM) Cost of Revenue ($ MM) Gross Margins (%) YoY Growth (%)
2021-12-31 3 1 78.19 1.28
2020-12-31 2 0 77.2 -1.14
2019-12-31 2 0 78.09 n/a
Date Reported Total Revenue ($ MM) Operating Expenses ($ MM) Operating Margins (%) YoY Growth (%)
2021-12-31 3 31 -1153.47 35.28
2020-12-31 2 36 -1782.18 -24.53
2019-12-31 2 32 -1431.14 n/a

The table above tells us that, on average, Neovasc has not been profitable over the last four years, which should be a warning sign to prospective investors. One bright spot, however, is that the company's operating margins are growing at an average yearly rate of 5.4%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.